- Home
- ABAT vs BEAT Comparison
ABAT vs BEAT Comparison
Compare ABAT & BEAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABAT
- BEAT
- Stock Information
- Founded
- ABAT 2011
- BEAT 2015
- Country
- ABAT United States
- BEAT United States
- Employees
- ABAT N/A
- BEAT N/A
- Industry
- ABAT Metal Mining
- BEAT Retail: Computer Software & Peripheral Equipment
- Sector
- ABAT Basic Materials
- BEAT Technology
- Exchange
- ABAT Nasdaq
- BEAT Nasdaq
- Market Cap
- ABAT 71.7M
- BEAT 65.1M
- IPO Year
- ABAT N/A
- BEAT 2021
- Fundamental
- Price
- ABAT $0.99
- BEAT $2.08
- Analyst Decision
- ABAT
- BEAT Buy
- Analyst Count
- ABAT 0
- BEAT 1
- Target Price
- ABAT N/A
- BEAT $8.00
- AVG Volume (30 Days)
- ABAT 2.1M
- BEAT 132.5K
- Earning Date
- ABAT 02-14-2025
- BEAT 03-19-2025
- Dividend Yield
- ABAT N/A
- BEAT N/A
- EPS Growth
- ABAT N/A
- BEAT N/A
- EPS
- ABAT N/A
- BEAT N/A
- Revenue
- ABAT $877,900.00
- BEAT N/A
- Revenue This Year
- ABAT $31,748.62
- BEAT N/A
- Revenue Next Year
- ABAT N/A
- BEAT N/A
- P/E Ratio
- ABAT N/A
- BEAT N/A
- Revenue Growth
- ABAT N/A
- BEAT N/A
- 52 Week Low
- ABAT $0.73
- BEAT $1.35
- 52 Week High
- ABAT $4.11
- BEAT $3.48
- Technical
- Relative Strength Index (RSI)
- ABAT 34.97
- BEAT 39.34
- Support Level
- ABAT $1.12
- BEAT $2.05
- Resistance Level
- ABAT $1.39
- BEAT $2.37
- Average True Range (ATR)
- ABAT 0.14
- BEAT 0.18
- MACD
- ABAT -0.03
- BEAT -0.02
- Stochastic Oscillator
- ABAT 2.42
- BEAT 21.24
About ABAT American Battery Technology Company
American Battery Technology Co is engaged in lithium-ion battery recycling, battery metals and material extraction, and resource production. It is a battery metals company producing low-cost battery metals with a commitment to closed-loop, clean energy technologies.
About BEAT Heartbeam Inc.
HeartBeam Inc is a medical technology company primarily focusing on developing and commercializing higher resolution ambulatory Electrocardiogram ("ECG") solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The Company's ability to develop higher-resolution ECG solutions is achieved through the development of the Company's proprietary and patented Vector Electrocardiography ("VECG") technology platform. The Company has validated this technology and is seeking U.S. Food and Drug Administration ("FDA") clearance for its initial telehealth products.